Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection

Tsan, Yu‐Tse; Lee, Chang-Hsing; Ho, Wen Chao; Lin, Meng‐Hung; Wang, Jung‐Der; Chen, Pau‐Chung

doi:10.1200/jco.2012.44.6831

Cited by 193 publications

(196 citation statements)

References 39 publications

Supporting

Mentioning

185

Contrasting

Order By: Relevance

“…Considerably longer follow-up will also be required to assess any benefit of statins on the long-term sequelae of NAFLD, i.e., cirrhosis and hepatocellular cancer (HCC). Notably, observational studies reported a decreased risk of HCC in patients treated with statins regardless of the cause (NAFLD, hepatitis B or C) [37][38][39] . Indeed, in a recent metaanalysis of 10 studies (n = 1459417), statins reduced the risk for HCC by 37% [37] .…”

Section: Effects On Liver Histologymentioning

confidence: 99%

Lipid-lowering agents in the management of nonalcoholic fatty liver disease

Τζιόμαλος¹

2014

WJH

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries and is associated not only with increased risk for liver disease-related complications but also with higher cardiovascular morbidity. Accordingly, lipid-lowering agents are frequently considered in these patients to reduce cardiovascular risk. However, there have been concerns regarding the safety of these agents in patients with chronic liver diseases. In the present review, we discuss the safety of lipid-lowering agents in patients with NAFLD as well as their effects on both cardiovascular and liver disease in this population. Accumulating data suggest that statins are safe in patients with NAFLD and that they reduce the increased cardiovascular morbidity of this population. However, it is still unclear whether statins are also useful as a treatment for NAFLD per se , since there are very limited and conflicting data on their effects on liver histology. There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD. Randomized controlled studies are needed to evaluate the role of lipid-lowering agents and particularly statins for the prevention of both cardiovascular and liver disease-related complications in this high-risk population. Core tip: Accumulating data suggest that statins are safe in patients with nonalcoholic fatty liver disease (NAFLD) and that they reduce the increased cardiovascular morbidity of this population. However, it is still unclear whether statins are also useful as a treatment for NAFLD per se , since there are very limited and conflicting data on their effects on liver histology. There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD.Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease.

show abstract

Section: Effects On Liver Histologymentioning

confidence: 99%

Lipid-lowering agents in the management of nonalcoholic fatty liver disease

Τζιόμαλος¹

2014

WJH

View full text Add to dashboard Cite

show abstract

“…Accordingly, statins have been shown to improve the antiviral activity of HCV polymerase and protease inhibitors in vitro (7), and are associated with an enhanced virologic response to peginterferon and ribavirin therapy in humans (8). In line with these pleotropic effects, statins have been reported to decrease the risk of HCC (9,10). A clinical trial also found a 9-month improvement in survival among advanced HCC patients treated with pravastatin (11).…”

Section: Introductionmentioning

confidence: 70%

Statin Use and Survival with Early-Stage Hepatocellular Carcinoma

Jeon

Goodman

Sundaram

2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Limited clinical and epidemiologic data suggest that statins may improve the outcomes of hepatocellular carcinoma (HCC), which has poor prognosis.Methods: We identified 1,036 stage I or II HCC patients, diagnosed between 2007 and 2009, through the linked Surveillance, Epidemiology, and End Results (SEER) Program and Medicare claims database. Of these, 363 patients were using statin either at the time of their HCC diagnosis or afterwards. We conducted multivariable Cox regression analysis to estimate the time-dependent effect of statin on survival. The analysis included age,

show abstract

“…Their study also discovered that an accumulated dose of statins of <215.4 DDD reduced HCC risk by 38% among patients, compared with those who did not receive statins. They concluded that an accumulated dose of statins of >215.4 DDD was not associated with any significant differences, which they similarly attributed to an inadequate sample size [2][3][4]. However, it was determined in the present study that cumulative daily dose, cumulative days, and average daily dose were all linearly correlated (P<0.001) regarding the correlation between statin drug usage and HCC risk among the patients with DM and either hepatitis B or hepatitis C. One possible reason for this discrepancy, in comparison to the study by Chiu et al [1] did not focus solely on whether receiving statin drugs could reduce HCC risk among patients with DM.…”

Section: Discussionmentioning

confidence: 99%

Ectopic Expression of DSCR1 in Conjunction with NDV Infection Reduces VEGF and Induces Apoptosis in Lung Cancer A549 Cell Line

Rad¹,

Boroujeni²,

Aleyasin³

2019

J Cancer Sci Ther

View full text Add to dashboard Cite

Objectives: To determine the relationship between the dose effect of Statin and the risk of HCC. Methods:This study was a case-control study. All participants were ≧ 50 years of age and were diagnosed with diabetes (ICD-9250.0x 0, 205.0 × 2) and were treated with an anti-diabetic agent for at least for 3 months according to the NHID, LHID2010 (longitudinal health insurance database 2010). We captured the use of a Statin before the index date in patients with type II diabetes. Patients diagnosed with a hepatoma (ICD-9:155) were defined as the case group. Results

show abstract

Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection

Abstract: Among patients with HCV infection, statin use was associated with reduced risk of HCC. Further research is needed to elucidate the mechanism responsible for this effect.

Cited by 193 publications

References 39 publications

Lipid-lowering agents in the management of nonalcoholic fatty liver disease

Lipid-lowering agents in the management of nonalcoholic fatty liver disease

Statin Use and Survival with Early-Stage Hepatocellular Carcinoma

Ectopic Expression of DSCR1 in Conjunction with NDV Infection Reduces VEGF and Induces Apoptosis in Lung Cancer A549 Cell Line

Contact Info

Product

Resources

About